| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 2.9K | 4.4% | 13.8% |
| Total Income | 2.9K | 4.3% | 13.6% |
| Expenditure | 2.4K | 5.5% | 10.7% |
| PBT | 547.17 | 4.3% | 39.7% |
| Net Profit | 389.32 | 8.2% | 38.8% |
| OPM | 22.31% | 1.70pp | 3.27pp |
| NPM | 13.26% | 1.82pp | 2.41pp |
| EPS | 14.79 | 6.6% | 32.8% |
Detailed report is being prepared.
Margin Expansion & Guidance Reset — Can Q2 Sustain Q1's Momentum?
After a blowout Q1 (PAT +72% YoY), management raised FY27 revenue guidance to 14–16% and EBITDA margins to 23%. The Street watches whether Q2 continues that growth and margin trajectory, and whether the raise signals genuine operational momentum or a one-time tailwind.
The Setup: Margin Narrative Shift
IPCA enters Q2 on the back of an exceptional first quarter: consolidated revenue grew 21% YoY to ~₹1,870 Cr, while PAT surged 72% YoY to ₹401.89 Cr, dragging margins to highs unseen in recent years. Management's response: a mid-year upgrade to FY27 revenue guidance (14–16%, up from 12–13%) and EBITDA margins (23%, up from 22%). This is not routine housekeeping — it signals management confidence that Q1's operating leverage is structural, not transient. Q2 is the test: does the company confirm that trajectory, or was Q1 a benefit-driven anomaly?
~14–16% YoY
per revised FY27 guidance; Q1 ran at +21%, so watch for normalization or further lift
~23% full-year target
raised from 22%; Q1 likely ran above this; see if Q2 sustains the tenor
12–13% FY27 guidance
stable guidance; street watches for this to be the slow leg or a floor
₹260–300 Cr FY27 target
on a smaller base; inflection signal if Q2 shows momentum here
What to Expect — Strong vs. Weak
A strong quarter would see Q2 revenue track toward the lower end of the 14–16% guidance (say, 13–15% YoY growth), EBITDA margins hold in the 22–23% range, and domestic formulations deliver 12–13% growth on track. Institutional business should show at least single-digit growth momentum; export/US business should sustain the 15–17% growth tenor from guidance. Consolidated PAT should expand double-digit YoY. A weaker than expected quarter would see revenue growth dip below 12%, margin compression from Q1's highs (say, sub-22% EBITDA), domestic formulations lagging 12% guidance, or institutional business stalling. Any miss in the export/US segment would flag headwinds in the higher-margin international push. Such a print would invite questions about whether the FY27 guidance reset was premature and demand management commentary on margin sustainability.
On Track for FY27?
Two quarters into the year: Q1 delivered 21% revenue growth and 72% PAT growth, well ahead of the 14–16% guidance range. If Q2 lands in the 13–15% growth range (reasonable given FY27 average target), the year-to-date run-rate would sit at ~17–18%, implying the H2 must moderate to 11–13% to hit the 14–16% FY27 target. This is plausible if Q1 benefited from one-time demand pull or favorable comparables, but it also raises the bar for management credibility: the H2 commentary will become critical. The 23% EBITDA margin guidance hinges on Q2 and H2 sustaining the operating leverage seen in Q1 — if Q2 shows margin compression, management will need to explain the path back to 23% for the year.
What the Street Says
Since Last Quarter
Board Meeting (Oct 22, 2026): Routine intimation of the Nov 5 board meeting to approve Q2 FY27 results. Insider Trading Window Closure (Sep 22, 2026): SEBI-compliant closure, suggesting management is cognizant of the quiet period — standard for a listed company. Shareholder Actions (Jul 14–Aug 13, 2026): A ₹6 per share dividend (600% of face value) was sanctioned and paid on Aug 7, signaling confidence in cash generation. Capex guidance remains at ₹700–800 Cr for FY27, with an additional ₹1 billion committed to biotech pilot and R&D — no major operational shifts flagged. Overall: No insider pledges, no adverse corporate actions, no regulatory commentary. The quarter is a pure operations print.
Watch List — Three Things for Result Day
1 · Domestic Formulations Trajectory
The 12–13% FY27 guidance assumes domestic formulations deliver mid-high teens growth; Q2 is the first real data point post-guidance reset. A miss here (sub-12%) would imply margin upside is fragile and concentrated in exports/institutional.
2 · EBITDA Margin Hold
Q1 likely ran above 23%; Q2 must show that margin is sustainable (at least 22–23% range). Compression below 21% would invite concerns that Q1 was driven by mix/one-time items rather than structural operational leverage.
3 · Institutional Business Momentum
FY27 guidance targets ₹260–300 Cr by year-end. Q2 data will signal whether this segment is accelerating or lagging. Any institutional slowdown would undermine the growth narrative and force management to explain path to FY27 target.
IPCA Laboratories reports Q2 FY27 results on November 5, 2026, with an exceptional Q1 (PAT +72% YoY, revenue +21%) and a mid-year guidance raise (14–16% revenue, 23% EBITDA margins) setting a high bar. The Street is 85.7% Buy, but valuation offers limited upside at current levels — the onus on Q2 is to confirm the raise is grounded in operational momentum, not temporary tailwinds. Domestic formulations growth (12–13% guidance), margin sustainability (watch for 22–23% EBITDA), and institutional traction (₹260–300 Cr FY27 target) will define the narrative. A strong print would vindicate the guidance lift and set up H2 momentum; a weak one would force management to walk back confidence and invite analyst re-rating risk.